Denali Therapeutics got an extension from the Food and Drug Administration for the review of its treatment for the genetic disorder Hunter syndrome. The target date for the license application review ...

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated ...

The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" ...

Sources from a University of Mississippi Press Release say that Liver cancer is the third-leading cause of cancer deaths ...

Policy brief urges balanced animal-research rules, offering science blogs NABR IUCN keywords and full statement.

Integrative approaches to addressing both mental and physical health may be the next step in successful treatment for ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces key ...

Denali Therapeutics (DNLI) announced that the FDA has extended its review timeline of the biologics license application seeking accelerated ...

Academic scientists and pharmaceutical companies alike are embracing artificial intelligence, even as questions linger about ...

“Future research will help clarify whether long-term music practice can strengthen the brain’s ability to process rhythm ...

We've all heard warnings about BPA—a chemical found in plastics and personal care products. Studies show that nearly 90% of ...